CLAIMS

1. An immunogenic composition comprising an antigen component and an adjuvant component, wherein

a) the adjuvant component comprises an emulsion containing oil, an immunostimulatory oligonucleotide, and at least one of:

i) a polycationic polymer; or

ii) a source of aluminum; and

b) the antigen component comprises 0.5 - 10 μg of FMD (Foot-and-Mouth Disease) virus composition per dose.

2. The immunogenic composition of claim 1, wherein:

a) said adjuvant component comprises the polycationic polymer,

b) said polycationic polymer is diethylaminoethyl (DEAE) Dextran.

3. The immunogenic composition of claim 1 or claim 2, wherein the immunostimulatory oligonucleotide comprises CpG.

4. The immunogenic composition of any one of claims 1-3, wherein the immunostimulatory oligonucleotide comprises at least 15 contiguous nucleotides of SEQ ID NO: 8.

5. The immunogenic composition of any one of claims 1-4, wherein said oily phase is present in the amount of up to 80% v/v of the composition.

6. The immunogenic composition of any one of claims 1-5, wherein the oily phase comprises 50.01%-55% v/v of the composition.

7. The immunogenic composition of any one of claims 1-6 further comprising one or more emulsifiers.

8. The immunogenic composition of any one of claims 1-7, wherein the adjuvant component comprises SEQ ID NO: 8 and diethylaminoethyl (DEAE) Dextran.

9. The immunogenic composition of any one of claims 1-8, wherein the DEAE Dextran is present in the amount of 6-200 mg per dose.

10. The immunogenic composition of any one of claims 1-8, wherein the immunostimulatory oligonucleotide is present in the amount of 6-200 μg per dose.

11. The immunogenic composition of any one of claims 1-10, wherein said FMD virus composition is a preparation of FMD virus Cruzeiro strain.

12. The immunogenic composition of claim 11, wherein said FMD virus Cruzeiro strain is genetically engineered.

13. The immunogenic composition of claim 12, wherein said FMD virus Cruzeiro strain contains a deletion of the leader coding region (LL).

14. The immunogenic composition of claim 12 or 13, wherein said FMD virus Cruzeiro strain contains negative antigenic markers introduced in one or both of the viral non-structural $3D^{pol}$ and 3B proteins.

15. The immunogenic composition of any one of claims 12-14, wherein said FMD virus Cruzeiro strain contains a heterologous capsid protein.

16. The immunogenic composition of claim 15, wherein the strain other than Cruzeiro is selected from Asia1, Turkey06, O1Campos, C3Indaial, and A2001-Argentina.

17. The immunogenic composition of any one of claims 1-16, wherein the antigen component comprises a 0.5 - 6 μg of FMD virus per dose.

18. The immunogenic composition of any one of claims 1-16, wherein the antigen component comprises a 0.5 - 4 μg of FMD virus per dose.

19. The immunogenic composition of any one of claims 1-16, wherein the antigen component comprises 0.5 - 2 μg of FMD virus per dose.

20. The immunogenic composition of any one of claims 1-16, wherein the antigen component comprises 0.5 – 1.5 μg of FMD virus per dose.

21. The immunogenic composition of any one of claims 1-20, wherein the FMD virus composition comprises both structural and non-structural FMD proteins.

22. An immunogenic composition according to any one of claims 1-21 for use in the treatment or prevention of FMD in an animal.

23. Use of an immunogenic composition of any one of claims 1-16 in the manufacture of a medicament for the prevention or treatment of FMD to manage the herd wherein, in said composition,

a) the antigen component comprises 6 - 10 μg of FMD virus composition per dose;
b) the immunostimulatory oligonucleotide comprises 75-200 μg per dose;
c) the polycationic carrier comprises 75-200 mg per dose;

and whereby upon suspected contact with FMD infection, the vaccinated members of said herd are either:

a) not slaughtered;
b) quarantined for 0-30 days; or
c) moved beyond the infected premises.

24. Use of an immunogenic composition of any one of claims 1-16 in the manufacture of a medicament for reducing the frequency of FMD persistence in a ruminant infected with FMD whereby the medicament is to be administered to said ruminant prior to the infection and wherein, in said composition,

a) the antigen component comprises 6 - 10 μg of FMD virus composition per dose;
b) the immunostimulatory oligonucleotide comprises 75-200 μg per dose;
c) the polycationic carrier comprises 75-200 mg per dose.

25. The use according to claim 23 or claim 24, wherein the vaccinated members of the herd are not slaughtered and are quarantined for 0-30 days.

26. The use according to any one of claims 23-25, wherein the herd is a bovine herd.

27. The use according to any one of claims 23-26, wherein the FMD virus composition is prepared by hollow fiber filtration.